Rare Variants in BNC2 Are Implicated in Autosomal-Dominant Congenital Lower Urinary-Tract Obstruction


Congenital lower urinary-tract obstruction (LUTO) is caused by anatomical blockage of the bladder outflow tract or by functional impairment of urinary voiding. About three out of 10,000 pregnancies are affected. Although several monogenic causes of functional obstruction have been defined, it is unknown whether congenital LUTO caused by anatomical blockage has a monogenic cause. Exome sequencing in a family with four affected individuals with anatomical blockage of the urethra identified a rare nonsense variant (c.2557C>T [p.Arg853*]) in BNC2, encoding basonuclin 2, tracking with LUTO over three generations. Re-sequencing BNC2 in 697 individuals with LUTO revealed three further independent missense variants in three unrelated families. In human and mouse embryogenesis, basonuclin 2 was detected in lower urinary-tract rudiments. In zebrafish embryos, bnc2 was expressed in the pronephric duct and cloaca, analogs of the mammalian lower urinary tract. Experimental knockdown of Bnc2 in zebrafish caused pronephric-outlet obstruction and cloacal dilatation, phenocopying human congenital LUTO. Collectively, these results support the conclusion that variants in BNC2 are strongly implicated in LUTO etiology as a result of anatomical blockage.

Congenital lower urinary-tract obstruction (LUTO) generally manifests as urinary bladder outflow obstruction, which can represent an anatomical blockage or a functional obstruction. LUTO of any kind has an estimated birth prevalence of three per 10,000 pregnancies. The largest population-based study from the West Midlands Congenital Anomaly Register in the UK suggests a significantly higher prevalence among black and minority ethnic groups than among white Europeans.

Little is known about the genetic causes of anatomical LUTO. Single cases in the literature are associated with trisomy 21 or chromosomal aberrations, but for the majority of cases, the origin of isolated anatomical LUTO remains unknown. Functional LUTO has been extensively genetically.

1Department of Pediatrics, Children’s Hospital, University Hospital Bonn, 53113 Bonn, Germany; 2Institute of Anatomy, University of Bonn, 53115 Bonn, Germany; 3Division of Nephrology, Department of Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, United States; 4Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany; 5Institute of Neuropathology, University of Bonn Medical Center, 53127 Bonn, Germany; 6Institute of Cardiovascular Regeneration, Center for Molecular Medicine, Goethe University, 60439 Frankfurt am Main, Germany; 7Division of Cell Matrix and Regenerative Sciences, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, United Kingdom; 8Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, United Kingdom; 9Institute of Pathology, University Hospital Bonn, 53127 Bonn, Germany; 10Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands; 11Department of Pediatrics and Nephrology, Medical University of Białystok, 15-089 Białystok, Poland; 12Department and Clinics of Pediatrics, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, 40-055 Zabrze, Poland; 13Department of Nephrology, Transplantology, and Internal Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland; 14Paediatric Urology, Royal Manchester Children’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, United Kingdom; 15Department of Urology, Pediatric Urology, Radboudumc Amalia Children’s Hospital, 6525 GA Nijmegen, the Netherlands; 16Department of Surgery—Pediatric Surgery, Radboudumc Amalia Children’s Hospital, 6525 GA Nijmegen, the Netherlands; 17Department of Pediatric Nephrology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Amalia Children’s Hospital, 6525 GA Nijmegen, the Netherlands; 18Department of Urology, Isala, 8025 AB Zwolle, the Netherlands; 19Department of Pediatrics, University Hospital Marburg, 35037 Marburg, Germany; 20Department of Obstetrics and Prenatal Medicine, University of Bonn, 53127 Bonn, Germany; 21Division of Pediatric Nephrology, Department of Pediatrics, University Hospital Bonn, 53129 Bonn, Germany; 22Cologne Center for Genomics, University of Cologne, 50931 Cologne, Germany; 23Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany; 24Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, 53127 Bonn, Germany; 25Department of Neonatology and Pediatric Intensive Care, Children’s Hospital, University of Bonn, 53127 Bonn, Germany; 26Department of Pediatrics, University of Zielona Góra, 56-417 Zielona Góra, Poland; 27Institute of Neuro-Anatomy, University of Bonn, 53115 Bonn, Germany

28These authors contributed equally

*Correspondence: b.odermatt@uni-bonn.de (B.O.), alina.hilger@uni-bonn.de (A.C.H.)

https://doi.org/10.1016/j.ajhg.2019.03.023.

© 2019 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
<table>
<thead>
<tr>
<th>Family</th>
<th>Individual</th>
<th>Sex</th>
<th>Phenotype</th>
<th>Age of clinical onset</th>
<th>Nucleotide change</th>
<th>Transcript</th>
<th>RefSeq</th>
<th>State</th>
<th>Chr. Pos.</th>
<th>Aminoacid change</th>
<th>Conserved to</th>
<th>Protein domain</th>
<th>GERP score</th>
<th>PPH (score)</th>
<th>SIFT (score)</th>
<th>CADD score</th>
<th>ACMG</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IV-2</td>
<td>male</td>
<td>distal urethral stenosis, BL VUR grade 5, urethral stenosis, bladder infections, pollakisuria with nycturia</td>
<td>13 weeks of gestation</td>
<td>c.2557C&gt;T</td>
<td>ENST00000418777</td>
<td>GenBank: NM_001317939.1</td>
<td>heterozygous</td>
<td>chr9: 16435054</td>
<td>p.Arg853*</td>
<td>drosophila melanogaster</td>
<td>c2h2 zinc finger domain</td>
<td>5.59</td>
<td>NA</td>
<td>deleterious (0)</td>
<td>25.7</td>
<td>pathogenic</td>
</tr>
<tr>
<td>2</td>
<td>III-4</td>
<td>female</td>
<td>meatal urethral stenosis, bladder desensus, pollakisuria with nycturia</td>
<td>12 years</td>
<td>c.2663A&gt;G</td>
<td></td>
<td>GenBank: NM_017637.6</td>
<td>heterozygous</td>
<td>chr9: 16419624</td>
<td>p.His888Arg</td>
<td>danio rerio</td>
<td>not known</td>
<td>NA</td>
<td>possibly damaging (0.981)</td>
<td>5.84</td>
<td>uncertain significance</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>III-2</td>
<td>female</td>
<td>urethral stenosis, pathological voiding on uroflowmetry</td>
<td>47 years</td>
<td>c.473C&gt;T</td>
<td>ENST00000380672</td>
<td>GenBank: NM_017637.6</td>
<td>heterozygous</td>
<td>chr9: 16552724</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>II-4</td>
<td>male</td>
<td>urethral stenosis</td>
<td>42 years at surgical correction</td>
<td>c.1036G&gt;C</td>
<td>ENST00000380672</td>
<td>GenBank: NM_017637.6</td>
<td>heterozygous</td>
<td>chr9: 16419624</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>III-1</td>
<td>male</td>
<td>normal RUS and renal function</td>
<td>38 years at finding of pathological uroflowmetry</td>
<td>c.13G&gt;A</td>
<td>ENST00000545497</td>
<td>GenBank: NM_017637.6</td>
<td>heterozygous</td>
<td>chr9: 16552724</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>male</td>
<td>PUV, VUR grade 1-2.5, bladder diverticles</td>
<td>7 years</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>heterozygous</td>
<td>chr9: 16552724</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I-1</td>
<td>male</td>
<td>PUV, VUR, ESRD</td>
<td>8 years</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>heterozygous</td>
<td>chr9: 16832274</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>male</td>
<td>PUV, VUR grade 1, incontinence until 6 years</td>
<td>~11 years</td>
<td>NA</td>
<td></td>
<td></td>
<td>heterozygous</td>
<td>chr9: 16832274</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued on next page)
defined, e.g., variants of CHRM3 (MIM: 118494) in prune-belly syndrome,\(^7\) variants of HPSE2 (MIM: 613469) and LRIG2 (MIM: 608869) in urofacial syndrome,\(^3,4\) and variants of MYH11 (MIM: 160745) and ACTG2 (MIM: 102545) in microcolon megabladder hypoperistalsis syndrome.\(^3,6\) Anatomical congenital LUTO can also be familial, albeit with interfamilial phenotypic variability, even between identical twins.\(^7-9\) Severe forms of LUTO are usually diagnosed prenatally on the basis of a distended bladder that fails to empty with dilatation of the upper urinary tract. However, milder forms manifest postnatally, often with recurrent urinary tract infections (UTI).\(^10\) Severe forms cause oligohydramnios and are associated with dysplastic kidney malformations that can be secondary to LUTO.\(^11\) This can be deduced because similar kidney disease occurs in ovine fetuses with surgically generated LUTO.\(^12\) Indeed, LUTOs are the leading cause for end-stage renal disease (ESRD) in children.\(^13\) The most common anatomical causes of LUTO are posterior urethral valves (PUVs) at the level of the prostatic urethra, a lesion unique to males.\(^14\) Less common are anterior urethral valves, also called urethral atresia, that can occur in either sex.\(^11,15\)

Here, we present evidence that monoallelic variants in BNC2, coding for basonuclin 2, are strongly implicated in isolated anatomical LUTO.

The study was conducted in adherence to the Declaration of Helsinki. The respective informed consent was obtained from the affected individuals or by proxies in the case of minors. The study was approved by the ethics committee of the medical faculty of the University of Bonn (No. 146/12) as well as by the respective ethics committees of the collaborating centers in Boston, Manchester, and Nijmegen (AGORA data and biobank). Human embryonic material, collected with maternal consent and ethical approval (REC 08/H0906/21+S), was sourced from the MRC-Wellcome Trust Human Developmental Biology Resource. Zebrafish and mice were kept according to national law and to general recommendations in our fish facility in Bonn, Germany and the mouse facility in Frankfurt, Germany, respectively.

We used exome sequencing in a previously unreported family (family 1; for a detailed description, see Supplemental Data and Table 1) whose affected members had autosomal-dominant LUTO of variable phenotypic expression (Figure 1C). The male index individual (IV-2) received vesicoamniotic shunting at 13 weeks of gestation as a result of early diagnosis of severe LUTO. Postnatally he was diagnosed with high-grade urethral stenosis. His mother (III-4) was diagnosed with urethral stenosis at the age of 16. Prior to her pregnancy with the index individual, she had two spontaneous abortions of unknown cause (Figure 1C). The maternal grandmother (II-4) was diagnosed with distal urethral stenosis (meatal stenosis) at the age of 47. Her sister (II-2) denied having voiding dysfunction but did not consent to any urological or genetic assessment. In accordance with the previously
Figure 1. Exome Sequencing and Targeted Re-sequencing in Families with LUTO Phenotype Identifies Variants in BNC2

(A and B) Exon structures of BNC2 cDNA of the two affected transcripts, ENST00000418777 and ENST00000380672, and protein domain structures are depicted. Positions of mutated nucleotides are indicated by arrows, and respective chromatograms are shown below. Evolutionary conservation among ortholog proteins is shown for family 2, carrying the p.His888Arg missense variant. The mutated amino acid residue is indicated with arrowheads and a red box. C2H2 = zinc-finger domain of the Cys2His2 folding group; C. elegans = Caenorhabditis elegans and D. melanogaster = Drosophila melanogaster.

(legend continued on next page)
described, well-noted, high within-family phenotypic variability, we considered her to be healthy. The female maternal cousin of the index individuals’ mother (II-2) was diagnosed with high-grade urethral stenosis at the age of 42.

Exome sequencing was performed on the affected individuals, II-4, III-2, and IV-2 from family 1 (Figure 1C). According to recent reports on rare dominantly inherited congenital anomalies of the kidney and urinary tract (CAKUT), we considered only variants with an allele frequency <0.0001.16,17 According to these filter criteria, we detected 11 missense and two nonsense variants that segregated in the family (Table S1). All variants were confirmed by Sanger sequencing. Among these variants, we prioritized the two nonsense variants as the most likely to be disease causing. One variant was found to be a novel p.Trp3* in ALB (MIM: 103600), encoding albumin. Recessive truncating variants in ALB have been described to cause analalbuminemia (MIM: 616000), whereas heterozygous variants in ALB can cause dysalbuminemic hyperthyroxinemia (MIM: 615999). Neither condition is associated with LUTO, and therefore the variant was not considered to be causative of the LUTO phenotype in the family. The second truncating variant, p.Arg853* rs1350162888 (ClinVar: SCV000854630) and three rare missense variants (c.13G>A [p.Val51le], ENST00000545497, rs750936655, allele frequency 0.000048) (c.473C>T [p.Thr158Ile], ENST00000380672, rs144242525, allele frequency 0.000012) (c.1036G>A [p.His888Arg], ENST00000380677, rs945575406, allele frequency 0.000004) in four independent individuals with LUTO (Table 1, Figure S2). The novel variant c.2663A>G, detected in an individual with PUV and severe secondary dilatation of his upper urinary tract (III-1, family 2, Figure 1E), was inherited from an affected father (II-1) who had a pathological uroflowmetry (Figure S1).

His renal ultrasound and renal function were normal. Investigation of the paternal grandparents (I-1 and I-2) showed that the variant was inherited from the healthy grandmother who did not have any history of UTI, polakkisuria, or nycturia and who had normal kidneys on renal ultrasound and normal uroflowmetry. The amino acid change p.His888Arg is highly conserved to D. melanogaster (GERP 5.59). Three in silico prediction programs classify the amino acid change as potentially disease causing and (according to the American College of Medical Genetics [ACMG] guidelines) as pathogenic (Table 1). The variant (c.2663A>G [p.His888Arg], ENST00000380672) is located in the fourth C2H2 zinc finger domain (Figure 1B). According to SwissProt entry Q6ZN30 and PROSITE, this variant is located near the second (residues 833–856) of three C2H2 zinc finger domains in BNC2 protein. However, InterPro and SMART include residue His888 in their signature matches (residues 833–856 and 861–888) for zinc-finger domains of the C2H2-type. These predictions suggest that this zinc finger’s very last histidine, which is replaced by arginine,
might interfere directly with the zinc finger domain’s ability to bind to specific DNA sequences. Moreover, PROFAcc and ISIS, implemented in the PredictProtein server,\textsuperscript{21,22} characterize His888 as an exposed residue, located in a protein-binding region. Because some C2H2 zinc-finger domains were also shown to facilitate binding to proteins or RNA,\textsuperscript{23} the substitution p.His888Arg in BNC2 might affect not only DNA, but also RNA, and/or might target protein binding. Because this novel variant has been transmitted from an affected father to his affected son and because this variant resides in a highly conserved functional domain of BNC2, we believe this variant to be possibly disease causing (Table 1).

Of the remaining three rare missense variants detected in BNC2, the first variant, c.13G>A, detected in a boy with PUV and severe dilatation of his upper urinary tract (vesicoureteral reflux [VUR]) and secondary ESRD, has been reported in a heterozygous context six times (in two male and four female carriers) in 124,816 alleles according to gnomAD (allele frequency 0.000048). The GERP conservation score, the benign classification of three \textit{in silico} prediction programs, and the ACMG guidelines suggest this variant to be benign. Parental DNA was not available for testing of inheritance (Table 1, family 5). The second rare missense variant, c.473C>T, detected in a male individual with PUV, has been mentioned in a heterozygous context three times (in one male and two female carriers) in 245,826 alleles according to gnomAD (allele frequency 0.000012). This variant is highly conserved and predicted by three \textit{in silico} prediction programs to be disease causing. Because the variant was transmitted from a father with unknown affection status, we considered this variant to be a variant of unknown clinical significance (Table 1, family 3). The third rare missense variant, c.1036G>C, was detected in a male individual with PUV. It has been mentioned only once in a heterozygous context (in one male carrier) in 245,816 alleles according to gnomAD (allele frequency 0.000004). Although the amino acid at this position is highly conserved, only two out of three \textit{in silico} prediction programs classified the variant to be disease causing. Parental DNA was not available for testing of inheritance (Table 1, family 4).

Hence, we classified the latter two missense variants, c.473C>T and c.1036G>C, each residing at a highly conserved amino acid position and predicted to be disease causing by at least two out of three \textit{in silico} prediction programs according to the ACMG guidelines, as variants of unknown clinical significance. In addition to these four missense variants, we detected four rare (minor-allele frequency <0.0001) and two novel synonymous variants and one rare intronic variant (minor-allele frequency <0.0001) within the direct vicinity to the respective splice site (Table S2). The novel synonymous variant c.1132A>C (p.Ser358Ser) was predicted by four splice-site analysis programs to have an impact on splicing at this site (Table S2). Nevertheless, it remains speculative whether splicing is affected, and further assessment of this variant is warranted.

Thereafter we sought to characterize the embryonic effects on the contribution of BNC2 to the formation of LUTO. BNC2 encodes a highly conserved zinc-finger protein of poorly understood function. The Human Protein Atlas reports expression of BNC2 in the cytoplasm of urothelial cells of the bladder. To study the expression of BNC2 in the human urethra, we performed immunohistochemistry staining with an anti-BNC2 antibody targeting a region in the N-terminal-vicinity third zinc finger of the canonical transcript ENST00000380672 (amino acids aa 661-787) and ENST00000418777 (aa 618–743). In a 7-week human embryo (Figure 2), BNC2 expression was detected in the urogenital sinus, the precursor of the bladder, and its outflow tract. The most prominent signal was in the primitive urothelium, and there was weaker immunoreactivity in the surrounding mesenchyme (Figure 2 A–D). Expression was also detected in the urothelium of the adult human male urethra (Figure S3). We performed expression analysis by \textit{in situ} hybridization (ISH) in mouse embryos by using a \textit{pan-Bnc2} probe that showed Bnc2 expression in the developing lower urinary-tract structures, with emphasis on the genital tubercle (gt) above the phallic urethra and below the pelvic urethra at embryonic day (E) 13.5 (Figures 2E–2G), the critical time point for urethral development. Expression of Bnc2 was also visible in the brain, in the mandibular region, and in dorsal parts above the spinal cord. The presence of the different \textit{Bnc2} mRNA (Bnc2-201 and Bnc2-214) in the urogenital region of developing mouse embryos was verified by Sanger sequencing. These mouse mRNA represent the two different homologous human transcripts that were found to be affected by the variants identified in family 1 (ENST00000418777) and family 2 (ENST00000380672). Our expression data for Bnc2 during murine development of the urinary tract and the existence of a heterozygous \textit{Bnc2} knockout mouse, which was reported by Bhoij et al.\textsuperscript{18} and presents with a cleft in the ventral part of the external genitalia, support the impact of \textit{Bnc2} in urethral development. Furthermore, Bhoij et al. describe homozygous knockout mice that have the same defect but in a more penetrant and severe form. These mice die soon after birth. Corresponding to that, the \textit{Bnc2} Δ/Δ knockout mice, as described by Vanhouttegem et al., die soon after birth. Because of their cleft palates and ingestion of air, these mice display aerial distention of their digestive tracts and therefore have distended abdomens.\textsuperscript{24} The urinary tract was not examined in these mice, although a distended abdomen is also observed in human newborns with LUTO.\textsuperscript{25}

In order to further investigate the function of BNC2 during urinary tract development, we used zebrafish as a model organism. Their embryonic kidney, the pronephros, consists of two nephrons, with a fused glomerulus, two tubules, and ducts. The ducts terminate in a cloaca, altogether reflecting a simplified model of the human nephron and urinary tract.\textsuperscript{26} BLAST analysis with human BNC2 identified a single zebrafish \textit{bnc2} ortholog.
encoding six different transcripts. To study the expression of \textit{bnc2} in zebrafish larvae (zfl), we generated a labeled RNA probe for ISH. We detected strong expression of \textit{bnc2} in the brain as described before \cite{27} but also in the pronephric ducts and the developing cloaca region at 33 hours post-fertilization (hpf) (Figure 2H). Expression of \textit{Bnc2} in the pronephric ducts was confirmed by immunohistochemistry analysis in developing zfl at 100 hpf (Figure 2I, 2J).

Next, we performed phenotypic analysis after a \textit{Bnc2} knockdown in developing zfl. We designed one specific antisense Morpholino (MO), targeting the translation initiation site of transcript \textit{bnc2}_202 (ENSDART00000128671.4).

The canonical transcript in zebrafish \textit{bnc2}_202 (ZFIN and Ensembl genome browser) is the most similar to the two human \textit{BNC2} transcripts that bear the discovered variants (ENST00000380672 and ENST00000418777). The zebrafish protein shows an amino acid similarity of 85%, similar protein structure, and a corresponding pattern of zinc-finger domains. The shorter 110 kDa version \textit{bnc2}_201 (ENSDART00000102322.6) is, as predicted, not targeted by the MO, as shown in the immunoblot analysis (Figure 3A).

Injecting embryos with 0.75 ng of \textit{bnc2} MO caused a distal pronephric outlet obstruction, which is illustrated by a “vesicle” at the cloacal region. This “vesicle” was
Figure 3. Depletion of Bnc2 Causes Pericardial Effusion, Hydrocephalus, Glomerular Cysts, and Distal Pronephric-Outlet Obstruction in Zebrafish

(A) Immunoblot analysis shows a protein decrease in bnc2 MO-injected zf1 for Bnc2-202 (130 kDa, C7DZJ6 according to UniProt ID) but not for Bnc2-201 (110 kDa, F1R42 according to UniProt ID) at 2 days dpf, which is as predicted for the specific MO target side. UI = uninjected.

(B) H&E staining of a sagittal section of a MO-injected zf1 (lateral view, head to the left) shows (PE), hydrocephalus (HY), abnormal body curvature and a “vesicle” due to an outlet obstruction of the pronephric ducts (arrowhead in enlargement in B) at 56 hpf.

(C) Zf1 injected with bnc2 MO frequently develop a distal-outlet obstruction at 33 hpf; this obstruction is highlighted by an arrowhead in the enlargement of (C).

(D) Whole-mount ISH with a pax2a probe relates the constituent parts of the bnc2 MO-induced pronephric-outlet obstruction to distal parts of the pronephric ducts and the cloacal region (black arrow).

(legend continued on next page)
detected in approximately 21% of bnc2 MO-injected larvae at 33 hpf (n = 399) but in 0% in controls (n = 500, p = 0.0001 [unpaired t test]); these results resemble those for the anatomical blockage found in the human individuals with LUTO (Figures 3B, 3C, and 3H).

Besides this strikingly specific phenotype, the bnc2 MO-injected zfl showed additional phenotypes such as abnormal body curvature (9%), hydrocephalus (HY) (5%), and pericardial effusion (PE) (44%). PE is sometimes considered to be nonspecific and is also seen in wild-type (WT) fish.26 However, because of the high number of bnc2 MO-injected zfl with PE, one might speculate that PE represents a secondary effect of kidney impairment. This has been described before in MO zebrafish experiments for mono-genic nephrotic syndrome.29 A previous study by Ogura et al. has shown abnormal body curvature in zfl overexpressing human BNC2; this abnormal curvature corresponds to a multifactorial etiology of human scoliosis.30 The etiology of HY remains elusive; a relation to the pronephric defect seems unlikely.

To further study the involvement of Bnc2 in formation of the distal pronephric outlet obstruction, or dilatation, in the cloacal region (inlays in Figures 3B and 3C), we performed ISH in bnc2 MO-injected zfl. A probe against pax2a, a marker for pronephric and cloacal tissue, indicated the intimate relation of the pronephric-outlet obstruction (Figures 3D and 3E). To further prove the specificity of the observed LUTO-like phenotypes, we generated an independent transient CRISPR/Cas approach in which we designed single guide RNA (sgRNA) targeting different genomic positions in bnc2. sgRNA-6-injected zfl developed pronephric-foutlet obstruction similar to that developed by the bnc2 MO-injected zfl at a rate of 5% at 33 hpf (n = 103) (Figure S4). Additionally, transient CRISPR/Cas Bnc2 knockout larvae showed slight body curvature and HY for sgRNA 4 at 2 days post-fertilization (dpf) and a generally reduced survival rate similar to that of the bnc2 MO zfl (Figure S4).

This strongly suggested that the observed zebrafish phenotypes were caused by Bnc2 knockdown after administering bnc2 MOs. Previously Lang et al., in an ENU-mutagenesis model, were able to show that bnc2+/− KO zfl present with HY and adult zebrafish present with disturbed pigmentation.27 In their study, the authors did not investigate their bnc2+/− KO zfl for anomalies of the pronephric ducts or the cloacal region.

To assess the impact of the discovered alleles in BNC2, we compared two of these variants in the same MO rescue approach as described above but co-injected mRNA carrying the respective variants instead of WT mRNA. Co-injection of human BNC2 mRNA bearing the p.His888Arg variant of family 2 did not result in a rescue of the pronephric outlet obstruction as observed with the WT mRNA (ENST0000380672) (Figure 3H). Consistently, co-injection of the same p.His888Arg BNC2 mRNA failed to
rescue the bnc2-MO-induced pronephric cysts in the Tg(wt1b:GFP) zfl (Figure 3I).

For the rescue experiments regarding the BNC2 transcript ENST00000418777 affected in family 1, we observed a tendency toward a decrease of the distal pronephric-outlet obstruction. Co-injection of BNC2 bearing the p.Arg853* variant showed no reduction of the specific phenotype (Figure S5).

The Bnc2 knockdown resulted in significantly reduced survival of zfl within 3 dpf (control [Ctrl] MO 94% versus bnc2 MO 36%) (Figure 3J). Although the co-injection of human WT BNC2 mRNA did not reduce mortality compared to that seen with solely bnc2 MO injection (bnc2 MO + WT RNA 69% [ENST00000380672]; bnc2 MO + WT RNA 63% [ENST00000418777]), we observed a slightly aggravated mortality in zfl co-injected with mutated BNC2 mRNA (bnc2 MO + p.His888Arg RNA 81% [ENST00000380672]; bnc2 MO + p.Arg853* RNA 88% [ENST00000418777]). We hypothesize several explanations for the failed rescue of mortality: general toxicity of mRNA, ubiquitous unregulated expression of BNC2, and the use of orthologous human mRNA in the zfl model. The distal pronephric-outlet obstruction is a very specific phenotype resembling the human LUTO phenotype, and because this obstruction can be rescued by human WT but not by mutated BNC2 mRNA, the data clearly demonstrate the role of BNC2 variants in LUTO.

We also employed an acute multi-sgRNA (mgRNA) approach targeting different positions in bnc2. This mgRNA resulted in median likelihoods of >99% for at least one variant on each allele deletion profiles, which were analyzed with the ICE synthego tool. We observed significantly reduced survival (50% median survival at 7 dpf) in zfl injected with bnc2 mgRNA (sgRNA 2, 6, and 8) over a time period of 21 dpf in comparison to zfl injected with scrambled sgRNA (Ctrl) and uninjected larvae (UI) and 40% survival at the end of the experiment (Figure S1E). A distal-outlet obstruction of the pronephric ducts was detected in 3% of bnc2-mgRNA-injected embryos at 33 hpf (n = 35).

Our hypothesis that the “cloacal vesicle” is derived from pronephric tissue and represents a pronephric-outlet obstruction at the cloacal opening was supported by bnc2 knockdown in the mmr2/hlx9b enhancer trap line Tg(HGj4A), which expresses GFP in the pronephric ducts during development. Expression of GFP in cells lining the inner wall of the MO-induced pronephric-outlet obstruction clearly demonstrated that they belong to the distal pronephric duct (Figure 4A). High-resolution 3D stack imaging not only showed the connection of the pronephric ducts to the pronephric outlet obstruction but also exhibited dilatation of the distal part of the pronephric ducts (Figures 4B–4D). This finding is consistent with the observed dilatation of the proximal pronephric duct in the Tg(wt1b:GFP) line (Figure 3G, asterisks). Injecting a cell tracer dye, CellTracker Red CMTPX, into the pronephric-outlet obstruction at 33 hpf showed that the cells forming the “vesicle” become part of the distal pronephric duct and cloaca later in development (56 hpf and 74 hpf) as the pronephric-outlet obstruction eventually “ruptures” between 36 and 40 hpf (Figure S6).

In zebrafish, formation of the cloaca and opening occurs around 24–30 hpf through programmed cell death of epidermal cells. Thus, we speculated that Bnc2, potentially acting as a transcription factor, controls the cell fate of the cloacal and pronephric-duct cells. Performing immunohistochemistry staining analysis with an anti-cleaved caspase 3 antibody, we detected a higher rate of apoptosis around the cloacal region and distal pronephric duct in bnc2 MO zebrafish at 1 dpf and 2 dpf, suggesting that bnc2 affects programmed cell death and leads to increased apoptosis (Figures 4E–G). One might speculate that the pronephric-outlet obstruction is causing retention of urine and that the resulting higher pressure in the pronephric ducts secondarily damages pronephric nephron cells and possibly the glomerular tissue and ultimately leads to cystic dilatation. However, the exact mechanism leading to the cloacal anomalies in bnc2 MO-injected zfl remains elusive.

Several phenotypic features observed in bnc2 MO-injected zfl (e.g., HY and cystic alterations of the kidneys) resemble features of the ciliopathy disease spectrum. Cells forming the pronephric duct normally exhibit multiple cilia that propel excreted urine toward the cloaca. Therefore, we were interested in determining whether cilia are morphologically altered in our knockdown morphants. Using immunofluorescence staining against acetylated tubulin and GFP in Tg(wt1b:GFP) zfl, we observed normal cilia morphology, but we also observed dilatation of the pronephric duct as observed previously in bnc2 MO zfl at 56 hpf (Figures 4H and 4I).

Hence, after a Bnc2 knockdown in zfl, we observed phenotypic features resembling the human phenotypic LUTO spectrum. The pronephric-outlet obstruction reflects the anatomical blockage of human PUVs or urethral stenosis that leads to urine retention and consecutively to dilatation of proximal parts of the nephron. This dilatation could be demonstrated through the use of two transgenic lines. The pronephric cysts might resemble the kidney damage observed in human individuals with LUTO; such individuals often suffer from early-onset renal failure despite proper urine drain management.

To assess the impact of the discovered variants p.His888Arg (family 2) and p.Arg853* (family 1), we performed mRNA rescue experiments. Co-injection of bnc2 MO and human WT mRNA resulted in a reduction of the LUTO-specific phenotype, which could not be rescued by the respective mutated BNC2 mRNA (Figure 3H–I, Figure S5). Thereby, we provided strong evidence for a pathogenic effect for the BNC2 variants found in our index families (families 1 and 2).

The phenotypic spectrum of human LUTO phenotypes is broad and has displays interfamilial variability. Because milder forms can manifest at older ages, it must be assumed that within large control databases such as gnomAD, some
individuals with a particular disease-causing variant or genotype fail to express most if not all features of the disease in question. This phenomenon is known as “reduced (or incomplete) penetrance.” Reduced penetrance is not uncommon; indeed, there are many known examples of “disease-causing variants” that fail to cause disease in a proportion of their carriers. As one example of such genes, HNF1B can be mentioned. Here, besides a variable phenotype even within families carrying the same variant, apparently unaffected family members could also be found to carry variants. Reduced penetrance might therefore explain not only why monogenic diseases are occasionally transmitted through unaffected parents but also why healthy individuals can harbor quite large numbers of potentially disadvantageous variants in their genomes without suffering any clinically obvious phenotypes. Reduced penetrance can be a function of the specific variant(s) involved or of allele dosage. It might also result from differential allelic expression, copy-number variation, or the modulating influence of independent genetic variants. The penetrance of some pathogenic genotypes is known to be age- and/or sex-dependent. Variable penetrance might also reflect the action of unlinked modifier genes, epigenetic changes, or environmental factors. Supporting this observation of incomplete penetrance in humans, our bnc2 MO and CRISPR knockdown fish show a phenotypic spectrum ranging from pronephric cysts in 57% (in bnc2 MO) to a visible pronephric-outlet obstruction (“vesicle”) in 21% and 3%, respectively. Because PUVs, the most common human LUTO phenotype, are limited to males, one would expect to find a higher number of female than male carriers for monoallelic disease-causing variants among healthy control individuals. This circumstance might in part explain why all heterozygous carriers (n = 5) reported in gnomAD for the truncating variant p.Arg853* identified in our family 1 are females.

Figure 4. Distal Pronephric-Outlet Obstruction Is Formed by Pronephric Tissue and Causes Dilated Pronephric Ducts and Increased Apoptosis

(A) Tg(HGj4A) GFP-reporter zfl (lateral view) injected with bnc2 MO emphasize the belonging of the distal pronephric-outlet obstruction, visible as a “vesicle” (marked with a white asterisk), to the distal pronephric duct and cloaca. The enlarged inlay shows the same “vesicle” in the sole bright-field image.

(B and C) High-resolution two-photon microscopy dorsal view of the cloacal region (white asterisks) in Tg(HGj4A) zfl injected with Ctrl MO (B) and bnc2 MO (C) indicates the intimate relation of the pronephric-outlet obstruction to the bilateral pronephric ducts. Widths of the pronephric-duct lumen are indicated with white arrows.

(D) Quantification of pronephric-duct widths in Tg(HGj4A) zfl injected with bnc2 MO shows significantly (p = 0.0002, Student’s t test) dilated pronephric ducts compared to controls. PD = pronephric ducts. Data are presented as means with SEM.

(E-G) Cleaved caspase 3 staining in bnc2 MO-injected zfl (56 hpf) shows an increased rate of apoptosis (black arrowheads in G) compared to Ctrl MO-injected embryos (E–F) around the pronephric duct (marked by red lines), the cloacal region, and the central nervous system (not shown). An overview emphasizing and localizing the pronephric regions shown in (F) and (G) is shown in H.

(H and I) Dorsal image from immunofluorescence staining of acetylated tubulin-stained cilia (red, acetTub) and GFP (green) depicts normal cilia morphology in the pronephric ducts in Tg(wt1b:GFP) zfl injected with Ctrl MO (H) and bnc2 MO (I) at 56 hpf. Pronephric ducts are widened in the bnc2 MO zfl as mentioned before. White arrowheads point to glomerular cysts in the bnc2 MO zfl. The sole acetylated-tubulin stain (red channel) emphasizes cilia morphology in the respective enlargement inlays of (H) and (I).

Scale bars represent 200 μm (A), 50 μm (magnification of A–C), 100 μm (E–G), 50 μm (H and I), and 25 μm (magnifications of H and I). *** p < 0.0005.
urinary-tract development across different species and suggest that \textit{bnc2} deficiency in \textit{zfl} causes pronephric-outlet obstruction and cystic anomalies of the pronephros and thereby phenocopies human LUTO. In conclusion, here we present evidence that monoallelic variants in BNC2, coding for basonucin 2, are strongly implicated in human LUTO with anatomical blockage of the urethra.

**Supplemental Data**

Supplemental Data can be found online at https://doi.org/10.1016/ajhg.2019.03.023.

**Acknowledgments**

We thank affected individuals and their parents for participation in this study together with the German self-help organization for children with LUTO. We thank Mieczysław Litwin (The Children’s Memorial Health Institute, Warsaw), Monika Miklaszewska, Katarzyna Zachwieja (Jagiellonian University, Cracow), Grażyna Krzemiń, Agnieszka Szmięlska (Medical University of Warsaw), Marcin Tkaczuk, Daria Tomczyk (Polish Mothers Memorial Hospital Research Institute, Łódź), Przemysław Sikora (Medical University of Lublin)—all from Poland—for recruiting affected individuals. C.M.K. is supported by Scimed BONFOR grants O-149.0120 and O-167.0021. G.C.D. and A.C.H. are supported by BONFOR grants O-120.0001 and O-149.0123. H.R. and M.L. are supported by grants LU 731/3-1 and RE 1723/2-1 from the German Research Foundation (DFG). L.v.d.Z. is supported by the Dutch Kidney Foundation (Kolff grant No. 1300KJ36) and a ZonMW-VENI grant (016.186.036; the Netherlands Organisation for Scientific Research). F.H. is supported by the National Institutes of Health grant DK- 088767. N.W. is supported by DFG grant GR4745/1-1. P.S. and P.G. are supported by the DFG Excellence Cluster Cardio-Pulmonary System (Exc147-2). Purchase of the 2p microscope used in this study was supported by grant INST 1172/37-1 FUGG (DFG). Zebrafish work was supported by Bonn medical faculty zebrafish core facility. \(T_{g}(\text{wt1b:GFP})\) zebrafish were provided by Christoph Englert and \(T_{g}(\text{HGb4A})\) zebrafish by Koichi Kawakami. W.G.N., H.M.S., R.M.C., G.M.B., and A.S.W. are supported by grants from Kids Kidney Research and Newlife. E.M.L. and A.S.W. acknowledge support from Horizon 2020 Marie Sklodowska-Curie Actions RENALTRACT (942937). The MRC-Wellcome Trust Human Developmental Biology Resource provided human embryonic material.

**Declaration of Interests**

The authors declare no competing interests.

Received: September 21, 2018
Accepted: March 22, 2019
Published: May 2, 2019

**Web Resources**

- Blood eQTL browser, https://www.genedenetwork.nl/bloodeqtlbrowser/

GTEx Portal, https://www.gtexportal.org/home/
ICE SYNTHEGO tool, https://ice.synthego.com/
PolyPhen, http://genetics.bwh.harvard.edu/pph2/
RegulomeDB, http://regulomedb.org/
SIFT, https://sift.bii.a-star.edu.sg/
SNP Annotation and Proxy search (SNAP no longer available), https://www.broadinstitute.org/snap/snap/
T1Dbase, http://www.t1dbase.org
The Human Protein Atlas, https://www.proteinatlas.org/
Zfin, https://zfin.org/

**References**


